Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: J Addict Med. 2018 May-Jun;12(3):227–233. doi: 10.1097/ADM.0000000000000392

Figure 3.

Figure 3

Secondary study outcomes. (a) Effects of assessment time and medication condition on QSU Factor 1 scores. (b) Effects of assessment time and medication condition on AUQ scores. Capped bars are SEM. Bracket with * indicate significant differences between placebo and active medication conditions (p < .05). Reported values are adjusted for significant covariates. Varenicline dose was 2 mg/day and naltrexone dose was 25 mg/day.